Boston Scientific to enhance urology portfolio by acquiring Axonics in $3.7bn deal
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a leading medical technology company specializing in urinary and bowel dysfunction devices. The acquisition, valued at $71 per share in cash, reflects an equity value of approximately $3.7 billion and an enterprise value of about $3.4 billion. Addressing […]